Trial Profile
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently With Platinum-based Chemoradiation Therapy in Patients With Locally Advanced, Unresectable NSCLC (Stage III) (PACIFIC2)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Jan 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Carboplatin; Cisplatin; Etoposide; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms PACIFIC-2
- Sponsors AstraZeneca; AstraZeneca AB
- 11 Jan 2024 Planned End Date changed from 5 Sep 2024 to 31 Oct 2024.
- 14 Nov 2023 Primary endpoint has not been met. (Progression-free survival (PFS)), according to an AstraZeneca Media Release.
- 14 Nov 2023 Results presented in an AstraZeneca Media Release.